Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADDEMFEP: Empagliflozin Dosing in HFpEF
NCT06683053Phase 3Active, not recruiting
- Start
- Mar 2023
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of empagliflozin in heart failure with preserved ejection fraction (HFpEF). Started Mar 2023; status: active, not recruiting.
02
Drugs
empagliflozin
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT06683053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06683053.